These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 2728673

  • 1. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U, Johannsen B, Elling D.
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [Abstract] [Full Text] [Related]

  • 2. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G, Zippel HH, Würz H.
    Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R, Hafter R, Schmid L, Babic R, Ulm K, Gössner W, Graeff H.
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [Abstract] [Full Text] [Related]

  • 5. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D, Paunović R, Paunković N.
    Jugosl Ginekol Perinatol; 1989 Jan; 29(3-4):83-5. PubMed ID: 2601371
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S.
    Anticancer Res; 1988 Jan; 8(4):761-4. PubMed ID: 3178164
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P, Salzer H, Dittrich C, Spona J.
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [Abstract] [Full Text] [Related]

  • 12. The role of the CA 125 assay in the management of ovarian cancer.
    Niloff JM.
    Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
    Kamiya N, Mizuno K, Kawai M, Kano T, Furuhashi Y, Tomoda Y.
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Tumor markers in gynecologic diseases].
    Geyer H, Kleine W.
    Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.